BioSpace News Archive

Wheeler Bio, Inc. today announced the appointment of Marc Helouin as Chief Quality and Regulatory Officer (CQRO).

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced the results of the first six months and second quarter ending June 30, 2023 and provided a corporate update.

Calliditas Therapeutics AB announced publication in The Lancet of the full data from the Phase 3 NefIgArd Study with Nefecon® delayed release capsules/Kinpeygo®) in adults with Primary IgA nephropathy.

Asieris Pharmaceuticals announced that the Government of Hong Kong Special Administrative Region Department of Health has approved the registration applications for the Uro-G and Uro-V disposable cystoscopic system.

Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States and a leading research center for diabetes and other life-threatening illnesses, have identified a cell metabolism process found in men with diabetes and metastatic prostate cancer that could one day lead to improved testing and treatments for Black men with these diseases.

The EGM resolved to authorise the Board of Directors to, during the period up to the Annual General Meeting 2024, resolve on issue of new common shares with preferential rights for the company’s shareholders.

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, announced that the US Patent and Trademark Office has rejected the relevant claims of the ‘483 patent that Magnolia Medical asserted against Kurin.

Merakris Therapeutics has added two new executives to its leadership team as it prepares to expand its product line and increase its investigational new drug programs aimed at treating patients with chronic skin and tissue wounds that fail to heal properly.

Tiziana Life Sciences Ltd. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer’s disease.

Milestone Scientific Inc., a leading developer of computerized drug delivery instruments that provide painless and precise injections, provided a business update and announced financial results for the second quarter ended June 30, 2023.